SUMMARY
Topical cutaneous local anaesthesia prior to venepuncture has become routine practice in most paediatric centres. Recently, amethocaine formulated for topical cutaneous anaesthesia has been shown to provide effective anaesthesia for venepuncture 1 . It has the advantage of a more rapid onset and longer duration of action after removal than EMLA™(Astra Pharmaceuticals Pty Ltd) 1 . In the first 18 months since its introduction to this institution, topical cutaneous 4% amethocaine gel has been used for over 20,000 procedures. Sporadic cases of severe localized reaction have been reported to our pharmacy. We present two cases of localized reaction to amethocaine, one involving occupational exposure, and results of an audit we conducted to investigate the incidence of reactions in patients.
CASE REPORTS
In the first case 4% amethocaine anaesthetic gel ("An gel", Pharmacy Department, Royal Children's Hospital) was applied before insertion of an intravenous cannula in the emergency department. Within five minutes, the patient, a four-year-old boy with no previous exposure to "An gel", complained of intense pain at the site of application. The discomfort did not subside and the cream was removed after 15 minutes. The skin appeared red and inflamed, "burnt", where the cream had been. Forty-eight hours later the skin blistered and peeled. The patient complained of a moderate degree of pain until healing of the skin was complete.
The second case involved a staff anaesthetist who suspected that occupational exposure to "An gel" was causing localized erythematous reactions lasting several days. To test this hypothesis "An gel" was applied to the skin of the inner forearm for 60 minutes, at which time an erythematous area was noted. The skin later blistered. This resolved slowly over a two-week period. There was no associated pain or systemic effects.
AUDIT

Methods
Amethocaine is prepared in our hospital pharmacy as a 4% cream in a 6% methylcellulose base ("An gel"), for use within our hospital. The 4% concentration of cream was selected on the basis of use of topical amethocaine overseas at either 3% or 4% strength. For a four-week period all patients presenting to our Day Surgery Unit who had "An gel" applied had our usual observations of the site formally recorded. Our routine is to apply the "An gel" to an area of skin 1.5 X 1.5 cm under an occlusive Tegaderm™ dressing for a minimum time of 30 minutes to achieve satisfactory cutaneous analgesia. A standard data collection form was used for each patient. The appearance of the skin was documented at the time of removal of cream for venepuncture, in the recovery room and prior to discharge. Skin appearances were classified as: normal (N), simple erythema-simple reddening of the skin (SE), raised erythema-reddening and oedema of the skin (RE), urticaria (U) and other. This classification was based on adverse reactions previously reported to our pharmacy. Duration of "An gel" application, previous exposure to anaesthetic cream, in particular "An gel", and any other adverse reactions were recorded. As part of our hospital's routine practice, all Day Surgery Unit patients are contacted by telephone 24 hours after the procedure. Details of progress of reactions to "An gel" or the occurrence of delayed reactions were sought at this time.
The incidence of reactions under various circumstances was compared using Fisher's Exact Test or a χ 2 test using GraphPad Instat statistical software.
Results
A total of 372 patients attending were surveyed. Of these 272 had a full set of observations completed. None of the 100 patients with incomplete data had significant localized reactions at the time of discharge. Summary data below describes the 272 with complete data collection.
The mean duration of application of the "An gel" was 120 minutes, with a range of 10 to 305 minutes. The mean total observation period (initial application to discharge) was 290 minutes.
Patients who experienced oedematous/urticarial reactions had not previously been exposed to amethocaine cream. Some patients who experienced simple, transient erythema had previously been exposed. None of these patients developed other reactions.
The incidence of various appearances of the skin at the three observation times are detailed in Table 1 . The tendency for abnormal appearances to resolve by discharge was confirmed by analysing the number of patients with normal and abnormal appearance of the skin at the "An gel" application site at the time of removal of the gel with the numbers in each group at discharge. (Fisher's Exact Test: two-sided P<0.0001, odds ratio 0.43, 95% confidence limit of odds ratio 0.28 to 0.64).
There was no statistically significant association between duration of amethocaine cream contact with patient skin and incidence of local reactions ( Table 2 ). Comparing normal versus abnormal skin reactions and combining all patients with less than 60 minutes application time (due to the small numbers in the <30 min group), a χ 2 test produced a P value of 0.64. Telephone follow-up at 24 hours revealed no significant problems associated with amethocaine cream. No case of delayed resolution of skin changes, as in our case reports, was detected in this cohort of 372 patients, suggesting that the upper 90% confidence limit for the true incidence of reactions with delayed resolution is about 0.008.
Discussion: Our results are in keeping with published data regarding the incidence of local reactions, in particular simple local erythema [2] [3] [4] [5] . A small incidence of erythema and urticaria is also consistent with documented "flare" reaction with intradermal injection of amethocaine 3 . This is thought to be related to the potent vasodilator properties of amethocaine 2, 3 . The initial trials of commercially prepared amethocaine have not revealed significant local reactions beyond mild erythema and oedema or urticaria 1, 6 . Our data supports these conclusions. The reduction in the incidence of abnormal skin appearances between removal of the cream and discharge and the absence of significant problems at 24 hour follow-up suggests that most reactions rapidly and spontaneously resolve.
Duration of analgesic action of amethocaine cream is longer with increased application times, but with an average duration of action of 3.8 hours following 30 minutes contact time (4.5 hours after 60 minutes) prolonged application is not necessary our data, the practicalities of a busy day surgical facility revealed a wide range of application times (range 10 to 305 minutes, mean 120 minutes). It is reassuring in the light of such variation that increased duration of application and repeated applications does not increase the likelihood of adverse reaction 2 . Our data support this conclusion. In the current economic climate it is notable that our hospital has made major cost savings by preparing amethocaine in methyl cellulose for routine topical analgesia of skin, compared with the cost of the commercially available topical cutaneous anaesthetic that was previously used.
CONCLUSION
We conclude from our survey that amethocaine gel is a safe and effective topical analgesic. We suggest that patients (and their parents) can be reassured that reactions are infrequent, usually mild and usually resolve rapidly and spontaneously. Widespread usage has resulted in the detection of rare subjects who have more severe local reactions as described in our case reports. It would seem prudent to remove the cream rapidly in patients reporting pain after application and to minimize occupational contact. If significant reactions occur, these should be documented in the medical notes and the patients informed in writing of the type of cream involved so that alternative methods can be used if required in the future.
